What is Biolinq?
Biolinq is a healthcare technology company dedicated to redefining the landscape of metabolic health through its proprietary biosensor platform. The company specializes in creating wearable devices that offer unparalleled simplicity, allowing users to monitor their health metrics with ease. By focusing on non-invasive, continuous data collection, Biolinq addresses critical gaps in current diagnostic tools, aiming to empower individuals with actionable insights. Its market position is bolstered by a robust intellectual property portfolio and a clear focus on improving patient outcomes through advanced, miniaturized sensing technology.
How much funding has Biolinq raised?
Biolinq has raised a total of $273.1M across 5 funding rounds:
Series A
$14.8M
Debt
$350K
Series B
$100M
Other Financing Round
$58M
Series C
$100M
Series A (2019): $14.8M with participation from M Ventures, LifeSci Venture Partners, Hikma Pharmaceuticals, Three Leaf Ventures, Aphelion Capital, and JDRF T1D Fund
Debt (2020): $350K led by PPP
Series B (2021): $100M supported by RiverVest Venture Partners
Other Financing Round (2024): $58M featuring Pegasus Tech Ventures and Alpha Wave Global
Series C (2025): $100M backed by Alpha Wave Global, Hikma Ventures, Aphelion Capital, M5 Venture, AXA, Taisho Pharmaceutical Holdings, RiverVest Venture Partners, and LifeSci Venture Partners
Key Investors in Biolinq
Alpha Wave Global
A global investment firm that provides capital and strategic support to high-growth companies across various sectors, including technology and healthcare.
Hikma Ventures
The venture capital arm of Hikma Pharmaceuticals, focusing on digital health and life sciences investments to drive global healthcare innovation.
Aphelion Capital
A medical technology-focused investment firm that partners with companies to improve quality of care while reducing costs in the healthcare system.
What's next for Biolinq?
With this latest round of financing, Biolinq is well-positioned to accelerate its clinical development and commercialization efforts. The company is expected to focus on scaling its manufacturing capabilities and expanding its reach within the digital health ecosystem. As it moves beyond the development phase, the strategic support from its diverse investor base will be instrumental in navigating regulatory pathways and establishing the company's biosensors as a standard in metabolic health management. The focus remains on delivering a seamless user experience that bridges the gap between complex medical data and daily health maintenance.
See full Biolinq company page
